EU "soft-justice" for Boehringer Ingelheim but are patent thickets legal?
This article was originally published in Scrip
The European Commission has dropped its investigation into allegations made by the Spanish firm, Almirall, that Boehringer Ingelheim had misused the patent system to exclude potential competition in the chronic obstructive pulmonary disease space. The two companies have reached an agreement, the commission announced yesterday.
You may also be interested in...
Brazil’s medicines regulator, ANVISA, finally has a new set of rules for the evaluation and marketing authorization of advanced therapy medicines.
Recommendations from the Alliance for Regenerative Medicine aim to improve cross-border healthcare to ensure patients can access advanced therapies.